Our patients did not receive new tests for molecular abnormalities, such as ASXL1, TP53, and RUNX1, which were recommended by the European LeukemiaNet guidelines in 2017.12 The choice of AML treatment was decided based on patient characteristics and was highly associated with all prognostic factors. The gene discussed is TP53; the disease is acute myeloid leukemia.